Xencor | XNCR - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
AbbVie USD 3.58B 316M 2026-03
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Amgen USD 1.58B 354M 2026-03
Arrowhead Research USD 41.74M 4.28M 2026-03
AstraZeneca USD 5.06B 455M 2026-03
Biogen USD 554.3M 128.2M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Cytokinetics USD 104.9M 13.17M 2026-03
GlaxoSmithKline GBP 2.12B 558M 2026-03
J&J USD 6.03B 719M 2026-03
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
MacroGenics USD 7.94M 1.96M 2025-12
Merck USD 2.67B 180M 2026-03
Novartis USD 3.14B 296M 2026-03
Pfizer USD 2.92B 1.16B 2026-03
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Roche Holding CHF 7.28B 3.99B 2025-12
Xencor USD 82.12M 65.08M 2026-03